Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer | OncLive

Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer

July 13, 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

The APT trial was an adjuvant study investigating 400 women with stage I HER2-positive breast cancer. The patients received treatment with trastuzumab and paclitaxel. There was a 97% 5-year disease-free survival showing encouraging results, states Burstein.


x